At the end, we will discuss the crosstalk between the pro-angiogenic factors like VEGF and aberrant cancer-associated signaling pathways to address the potential utility of targeting MUC1 oncoprotein in therapeutic strategies. The gene discussed is MUC1; the disease is cancer.